Q-omics provides the consensus-scored SNORA23 profile across patient tissues and cancer cell-line models. SNORA23 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, SNORA23 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, SNORA23 RNA expression shows 9,817 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight READ, COAD, and GBM as cancer lineages where SNORA23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA23 survival associations across molecular data types. SNORA23 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA23 RNA expression–survival associations across cancer types. High SNORA23 expression shows unfavorable associations in STAD, KICH and ACC, but favorable associations in READ, SKCM and THCA. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .008). Together, the overview and detailed table identify READ as the clearest survival context for SNORA23 RNA expression.
This table summarizes SNORA23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA23 shows higher tumor expression in COAD, STAD, HNSC, LUSC, BRCA and KIRP. The COAD box plot shows higher SNORA23 RNA expression in tumor versus normal tissue (log2 FC = +0.612, t-test p < 0.001).
This table shows molecular features associated with SNORA23 in patient tissues and cancer cell lines. In patient samples, SNORA23 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
